169 related articles for article (PubMed ID: 37111733)
1. Sustained-Release Powders Based on Polymer Particles for Pulmonary Delivery of Beclomethasone Dipropionate in the Treatment of Lung Inflammation.
Craparo EF; Drago SE; Costabile G; Ferraro M; Pace E; Scaffaro R; Ungaro F; Cavallaro G
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111733
[TBL] [Abstract][Full Text] [Related]
2. Realization of polyaspartamide-based nanoparticles and in vivo lung biodistribution evaluation of a loaded glucocorticoid after aerosolization in mice.
Craparo EF; Di Gioia S; Trapani A; Cellamare S; Belgiovine G; Mandracchia D; Giammona G; Cavallaro G; Conese M
Int J Pharm; 2016 Aug; 510(1):263-70. PubMed ID: 27326484
[TBL] [Abstract][Full Text] [Related]
3. Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate.
Triolo D; Craparo EF; Porsio B; Fiorica C; Giammona G; Cavallaro G
Colloids Surf B Biointerfaces; 2017 Mar; 151():206-214. PubMed ID: 28013164
[TBL] [Abstract][Full Text] [Related]
4. PHEA-graft-polybutylmethacrylate copolymer microparticles for delivery of hydrophobic drugs.
Licciardi M; Di Stefano M; Craparo EF; Amato G; Fontana G; Cavallaro G; Giammona G
Int J Pharm; 2012 Aug; 433(1-2):16-24. PubMed ID: 22575755
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids.
Craparo EF; Teresi G; Bondi' ML; Licciardi M; Cavallaro G
Int J Pharm; 2011 Mar; 406(1-2):135-44. PubMed ID: 21185363
[TBL] [Abstract][Full Text] [Related]
6. Inhalable polymeric microparticles as pharmaceutical porous powder for drug administration.
Craparo EF; Cabibbo M; Emanuele Drago S; Casula L; Lai F; Cavallaro G
Int J Pharm; 2022 Nov; 628():122325. PubMed ID: 36309290
[TBL] [Abstract][Full Text] [Related]
7. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate.
Gaber NN; Darwis Y; Peh KK; Tan YT
J Nanosci Nanotechnol; 2006; 6(9-10):3095-101. PubMed ID: 17048523
[TBL] [Abstract][Full Text] [Related]
8. Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations.
Sahib MN; Abdulameer SA; Darwis Y; Peh KK; Tan YT
Drug Des Devel Ther; 2012; 6():29-42. PubMed ID: 22393583
[TBL] [Abstract][Full Text] [Related]
9. Immediate Release Formulation of Inhaled Beclomethasone Dipropionate-Hydroxypropyl-Beta-Cyclodextrin Composite Particles Produced Using Supercritical Assisted Atomization.
Wu HT; Chuang YH; Lin HC; Hu TC; Tu YJ; Chien LJ
Polymers (Basel); 2022 May; 14(10):. PubMed ID: 35631996
[TBL] [Abstract][Full Text] [Related]
10. Polyaspartamide-Based Nanoparticles Loaded with Fluticasone Propionate and the In Vitro Evaluation towards Cigarette Smoke Effects.
Craparo EF; Ferraro M; Pace E; Bondì ML; Giammona G; Cavallaro G
Nanomaterials (Basel); 2017 Aug; 7(8):. PubMed ID: 28805713
[TBL] [Abstract][Full Text] [Related]
11. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
12. Engineering drug ultrafine particles of beclomethasone dipropionate for dry powder inhalation.
Xu LM; Zhang QX; Zhou Y; Zhao H; Wang JX; Chen JF
Int J Pharm; 2012 Oct; 436(1-2):1-9. PubMed ID: 22732674
[TBL] [Abstract][Full Text] [Related]
13. Polyaspartamide-Polylactide Graft Copolymers with Tunable Properties for the Realization of Fluorescent Nanoparticles for Imaging.
Craparo EF; Porsio B; Mauro N; Giammona G; Cavallaro G
Macromol Rapid Commun; 2015 Aug; 36(15):1409-15. PubMed ID: 26010226
[TBL] [Abstract][Full Text] [Related]
14. Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers.
Khan I; Hussein S; Houacine C; Khan Sadozai S; Islam Y; Bnyan R; Elhissi A; Yousaf S
Int J Pharm; 2021 Apr; 598():120376. PubMed ID: 33617949
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
Beeh KM; Kuna P; Corradi M; Viaud I; Guasconi A; Georges G
Int J Chron Obstruct Pulmon Dis; 2021; 16():79-89. PubMed ID: 33488071
[TBL] [Abstract][Full Text] [Related]
16. PHEA-PLA biocompatible nanoparticles by technique of solvent evaporation from multiple emulsions.
Cavallaro G; Craparo EF; Sardo C; Lamberti G; Barba AA; Dalmoro A
Int J Pharm; 2015 Nov; 495(2):719-27. PubMed ID: 26410757
[TBL] [Abstract][Full Text] [Related]
17. Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma.
Micheletto C; Guerriero M; Tognella S; Dal Negro RW
Respir Med; 2005 Jul; 99(7):850-5. PubMed ID: 15939246
[TBL] [Abstract][Full Text] [Related]
18. A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma.
Nathan RA; Nolop KB; Cuss FM; Lorber RR
Chest; 1997 Jul; 112(1):34-9. PubMed ID: 9228354
[TBL] [Abstract][Full Text] [Related]
19. Initial improvements in lung function and bronchial hyperresponsiveness are maintained during 5 years of treatment with inhaled beclomethasone dipropionate and terbutaline.
Douma WR; Kerstjens HA; de Gooijer A; Overbeek SE; Koëter GH; Postma DS;
Chest; 2002 Jan; 121(1):151-7. PubMed ID: 11796444
[TBL] [Abstract][Full Text] [Related]
20. [The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation].
Ohbayashi H
Arerugi; 2005 Jan; 54(1):24-35. PubMed ID: 15841673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
